Skip to main content
OPRX logo

OPRX · OptimizeRx Corp · Webcasts, Transcripts & Audio

Track OPRX — free
$9.32 -0.05 (-0.53%) At close · Oct 30 Q2 2026 earnings call transcript
Market Cap
$175.55M
Shares
18.84M
Volume · Oct 30 136.55K Avg daily vol (3M) 182.08K

OptimizeRx Corp Webcasts

Earnings calls, investor updates, investor days and conferences for OptimizeRx Corp (OPRX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-11-11
OptimizeRx Corp (OPRX) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-10
OptimizeRx Corp (OPRX) September 10, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
OptimizeRx Corp (OPRX) Q2 2026 Earnings Call Transcript
Positive tone Revenue and EBITDA performance AI-enabled product innovations Customer concentration and revenue softness
Revenue
$20.50M
▼ 29.8% YoY
Diluted EPS
$-0.04
▼ 150% YoY
Gross margin
76.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
OptimizeRx Corp (OPRX) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-12
OptimizeRx Corp (OPRX) Q1 2026 Earnings Call Transcript
Balanced tone Adjusted EBITDA and Margin Discipline Programmatic / DSP Activation Opportunity Term Loan Refinancing
Revenue
$19.84M
▼ 9.5% YoY
Diluted EPS
$-0.03
Gross margin
75.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Transcript
Positive tone Q4 and FY2025 financial performance Channel partners and competitive positioning DAP (Dynamic Audience Activation Platform)
Revenue
$32.24M*
▼ 0.2% YoY
Gross margin
74.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
OptimizeRx Corp (OPRX) Q3 2025 Earnings Call Transcript
Confident tone Rule of 40 and Profitability Omnichannel Platform and Technology Revenue Growth and Beat
Revenue
$26.07M
▲ 22.3% YoY
Diluted EPS
$0.04
Gross margin
67.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
OptimizeRx Corp (OPRX) Q2 2025 Earnings Call Transcript
Confident tone Revenue growth and financial outperformance Debt paydown and balance sheet Omnichannel platform and competitive positioning
Revenue
$29.20M
▲ 55.2% YoY
Diluted EPS
$0.08
Gross margin
63.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
OptimizeRx Corp (OPRX) Q1 2025 Earnings Call Transcript
Confident tone Gross margin and product mix Revenue growth and beat Pipeline and customer KPIs
Revenue
$21.93M
▲ 11.4% YoY
Diluted EPS
$-0.12
Gross margin
60.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-12
OptimizeRx Corp (OPRX) Q4 2024 Earnings Call Transcript
Confident tone 2025 guidance and growth outlook Rule of 40 and recurring revenue model HCP and DTC integration / competitive positioning
Revenue
$32.32M*
▲ 13.9% YoY
Gross margin
68.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
OptimizeRx Corp (OPRX) Q3 2024 Earnings Call Transcript
Positive tone DTC micro-neighborhood / self-service pivot Q3 revenue shortfall DAAP AI-driven omnichannel platform
Revenue
$21.31M
▲ 30.5% YoY
Diluted EPS
$-0.50
Gross margin
63.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
OptimizeRx Corp (OPRX) Q2 2024 Earnings Call Transcript
Positive tone DAAP conversion and momentum Medicx Health acquisition integration Full-year revenue guidance and visibility
Revenue
$18.81M
▲ 36.1% YoY
Diluted EPS
$-0.22
Gross margin
62.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-18
OptimizeRx Corp (OPRX) Q1 2024 Earnings Call Transcript
Confident tone DAAP (Dynamic Audience Activation Platform) Cross-sell and pipeline expansion Financial performance (gross margin, expenses, net loss)
Revenue
$19.69M
▲ 51.4% YoY
Diluted EPS
$-0.38
Gross margin
62.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-11
OptimizeRx Corp (OPRX) Q4 2023 Earnings Call Transcript
Confident tone DAAP Platform Growth Medicx Health Acquisition & Integration Cost Optimization
Revenue
$28.37M*
▲ 44.3% YoY
Gross margin
62.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
OptimizeRx Corp (OPRX) Q3 2023 Earnings Call Transcript
Revenue
$16.33M
▲ 8.3% YoY
Diluted EPS
$-0.17
Gross margin
60.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
OptimizeRx Corp (OPRX) Q2 2023 Earnings Call Transcript
Revenue
$13.82M
▼ 1.1% YoY
Diluted EPS
$-0.24
Gross margin
56.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
OptimizeRx Corp (OPRX) Q1 2023 Earnings Call Transcript
Revenue
$13.00M
▼ 5.3% YoY
Diluted EPS
$-0.37
Gross margin
57.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-08
OptimizeRx Corp (OPRX) Q4 2022 Earnings Call Transcript
Revenue
$19.65M*
▼ 3.2% YoY
Gross margin
63.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
OptimizeRx Corp (OPRX) Q3 2022 Earnings Call Transcript
Revenue
$15.09M
▼ 6.4% YoY
Diluted EPS
$-0.19
Gross margin
62.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
OptimizeRx Corp (OPRX) Q2 2022 Earnings Call Transcript
Revenue
$13.98M
▲ 2.6% YoY
Diluted EPS
$-0.21
▼ 1150% YoY
Gross margin
64.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
OptimizeRx Corp (OPRX) Q1 2022 Earnings Call Transcript
Revenue
$13.73M
▲ 22.3% YoY
Diluted EPS
$-0.21
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-15
OptimizeRx Corp (OPRX) Q4 2021 Earnings Call Transcript
Revenue
$20.31M*
▲ 23.7% YoY
Gross margin
61.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-10
OptimizeRx Corp (OPRX) Q3 2021 Earnings Call Transcript
Revenue
$16.12M
▲ 53.3% YoY
Diluted EPS
$0.00
Gross margin
56.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-27
OptimizeRx Corp (OPRX) Q2 2021 Earnings Call Transcript
Revenue
$13.63M
▲ 55.1% YoY
Diluted EPS
$0.02
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-28
OptimizeRx Corp (OPRX) Q1 2021 Earnings Call Transcript
Revenue
$11.23M
▲ 48.1% YoY
Diluted EPS
$-0.04
Gross margin
54.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
OptimizeRx Corp (OPRX) Q4 2020 Earnings Call Transcript
Revenue
$16.43M*
▲ 122.6% YoY
Gross margin
52.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-10-13
OptimizeRx Corp (OPRX) Q3 2020 Earnings Call Transcript
Revenue
$10.52M
▲ 110.3% YoY
Diluted EPS
$-0.02
Gross margin
57.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-23
OptimizeRx Corp (OPRX) Q2 2020 Earnings Call Transcript
Revenue
$8.78M
▲ 25.4% YoY
Diluted EPS
$-0.07
▼ 333.3% YoY
Gross margin
58.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-16
OptimizeRx Corp (OPRX) Q1 2020 Earnings Call Transcript
Revenue
$7.58M
▲ 45.6% YoY
Diluted EPS
$-0.15
Gross margin
57.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-28
OptimizeRx Corp (OPRX) Q4 2019 Earnings Call
Revenue
$7.38M*
▲ 12.2% YoY
Gross margin
60.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 webcasts
Key facts CIK 1448431 CUSIP 68401U204 13F (30d) 14 filings 14 filers Visit website Investor relations